E-News



Alliance NCTN/NCORP/AFT at 2019 ASCO

The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) convened in Chicago May 31-June 4 with Alliance Group Chair Monica M. Bertagnolli, MD, completing her 2018-2019 term as ASCO President. The ASCO meeting brings together more than 32,000 oncology professionals from around the world. This year's meeting theme was "Caring for Every Patient, Learning from Every Patient." Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship, were highlighted.  

Each year, ASCO attendees learn from leading-edge scientific presentations, including papers and talks from Alliance researchers, as well as thousands of scientific abstracts and research news developments. At this year's conference, Alliance investigators presented more than 15 abstracts, sharing the latest findings on breast cancer, head and neck cancer, lung cancer, GI and GU cancers, along with cancer control research. The Alliance was well-represented with dozens of researchers participating on panels, discussing new research and presenting posters.
 
Here's a snapshot of studies that Alliance researchers presented:

Breast Cancer
CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC)
First Author: William M. Sikov
Abstract No: 591 | J Clin Oncol 37, 2019 (suppl; abstr 591)
Poster Session (Board #83) | Sunday June 2, 8 am to 11 am | Location: Hall A

Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials
First Author: Aranzazu Fernandez-Martinez  
Abstract No: 571 | Citation: J Clin Oncol 37, 2019 (suppl; abstr 571)
Poster Session (Board #63) | Sunday June 2, 8 am to 11 am | Location: Hall A

Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance)
First Author: Mark Jesus Mendoza Magbanua
Abstract No: 1049 | Citation: J Clin Oncol 37, 2019 (suppl; abstr 1049)
Poster Session (board #130) | Sunday June 2, 8 am to 11 am | Location: Hall A

Gastrointestinal Cancer
Randomized trial of standard chemotherapy alone or combined withatezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502)
First Author: Frank A. Sinicrope
Abstract No: e15169 | J Clin Oncol 37, 2019 (suppl; abstr e15169)
Published online only

Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202)
First Author: Emily K. Bergsland   
Abstract No: 4005 | Citation: J Clin Oncol 37, 2019 (suppl; abstr 4005)
Oral Abstract Session | Session June 2, 9:45 am to 12:45 pm | Location: Arie Crown Theater  

Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials
First Author: Aziz Zaanan 
Abstract No: 3583 | Citation: J Clin Oncol 37, 2019 (suppl; abstr 3583)  
Poster Session (Board #75) | Monday June 3, 8 am to 11 am | Location: Hall A

Genitourinary Cancer
CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvantchemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC)
First Author: James A. Eastham
Abstract No: 5079 | Citation: J Clin Oncol 37, 2019 (suppl; abstr 5079)
Poster Session (Board #191) | Saturday June 1, 1:15 pm to 4:15 pm | Location: Hall A

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)
First Author: Michael J. Morris  
Abstract No: 5008 | Citation: J Clin Oncol 37, 2019 (suppl; abstr 5008)
Oral Abstract Session | Friday May 31, 2:45 pm to 5:45 pm | Location: Arie Crown Theater

CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma
First Author:Jonathan E. Rosenberg
Abstract No: 4503 | Citation: J Clin Oncol 37, 2019 (suppl; abstr 4503)
Oral Abstract Session | Monday June 3, 8 am to 11 am | Location: Arie Crown Theater

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)  
First Author: Tian Zhang
Abstract No: TPS4596 | Citation: J Clin Oncol 37, 2019 (suppl; abstr TPS4596)
Poster Session (Board #417a) | Monday June 3, 1:15 pm to 4:15 pm | Location: Hall A

Head and Neck Cancer
Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers  
First Author: Alan L Ho
Abstract No: 6020 | J Clin Oncol 37, 2019 (suppl; abstr 6020)
Poster Discussion Session (Board #9) | Saturday June 1, 1:15 pm to 4:15 pm | Location: Hall A and Saturday June 1, 4:30 pm to 6 pm | Location: S100a

Health Services Research, Clinical Informatics and Quality of Care
Modeling accrual of older adults to cancer clinical trials: (Alliance A151736)
First Author: Noam A. VanderWalde
Abstract No: e18132 | J Clin Oncol 37, 2019 (suppl; abstr e18132)
Published online only

Lung Cancer
Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance)
First Author: Arkadiusz Z. Dudek  
Abstract No: 8517 | Citation: J Clin Oncol 37, 2019 (suppl; abstr 8517)
Poster Discussion Session (Board #273) | Sunday June 2, 8 am to 11 am | Location: Hall A and Sunday June 2, 11:15 am to 12:45 pm Location: S406

Veliparib (Vel) in combination with chemoradiotherapy (CRT) of carboplatin/paclitaxel (C/P) plus radiation in patients (pts) with stage III non-small cell lung cancer (NSCLC) (M14-360/AFT-07)  
First Author: David E. Kozono
Abstract No.: 8510 | J Clin Oncol 37, 2019 (suppl; abstr 8510)
Poster Board: #266 | Sunday, June 2, 2019, 11:15 am - 12:45 pm | Location: S406

Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09)
First Author: Thomas A. Hensing  
Abstract No: 9088 | Citation: J Clin Oncol 37, 2019 (suppl; abstr 9088)
Poster Session (Board #411) | Sunday June 2, 8 am to 11 am Location: Hall A

Symptoms and Survivorship
Treatment completion and toxicity of trastuzumab or trastuzumab + lapatinib in older patients (pts): BIG 2-06; NCCTG N063D (Alliance)
First Author: Noam FalbelPonde  
Abstract No: 11553 | Citation: J Clin Oncol 37, 2019 (suppl; abstr 11553)
Poster Session (Board #245) | Monday June 3, 1:15 pm to 4:15 pm | Location: Hall A

 

 

For other articles in this issue of the Alliance E-News newsletter, see below.